Sustained reduction of aldosterone in response to the angiotensin receptor blocker Valsartan in patients with chronic heart failure: Results from the Valsartan heart failure trial

  • J.N. C
  • I.S. A
  • R. L
 et al. 
  • 4


    Mendeley users who have this article in their library.
  • N/A


    Citations of this article.


Background - Aldosterone has been implicated in the progression of heart failure. The Valsartan Heart Failure Trial (Val-HeFT) provided the first opportunity to examine the long-term effects of an angiotensin receptor blocker on plasma aldosterone levels in patients with NYHA class II through IV heart failure. Methods and Results - Plasma aldosterone was measured by radioimmunoassay in core laboratories at baseline and during follow-up in patients assigned to valsartan at a target dose of 160 mg twice daily or placebo. In the placebo group, aldosterone (baseline, 150±160 pg/mL, mean±SD; n = 2025) increased at 4, 12, and 24 months. In the valsartan group, aldosterone (baseline, 137±124 pg/mL, mean±SD; n = 2023) decreased at 4 months and remained suppressed for up to 2 years. At end point (last measurement in each patient), mean aldosterone increased by 17.8±3.0 pg/mL (SEM) (11.9%) in the placebo group and decreased by 23.8±3.0 pg/mL (SEM) (-17.4%) in the in the valsartan group (P

Author-supplied keywords

  • Aldosterone [blood]
  • Angiotensin Receptor Antagonists
  • Cardiac Output
  • Chronic Disease
  • Double-Blind Method
  • Follow-Up Studies
  • Humans[checkword]
  • Low [blood] [classification] [drug
  • Sr-vasc
  • Tetrazoles [therapeutic use]
  • Valine [analogs & derivatives] [therapeutic use]
  • Valsartan
  • aged
  • aldosterone
  • aldosterone blood level
  • aldosterone release
  • angiotensin receptor
  • angiotensin receptor antagonist
  • article
  • beta adrenergic receptor blocking agent
  • clinical trial
  • controlled clinical trial
  • controlled study
  • dipeptidyl carboxypeptidase inhibitor
  • disease course
  • double blind procedure
  • drug efficacy
  • female
  • follow up
  • heart failure
  • hormone inhibition
  • hormone inhibitor
  • human
  • major clinical study
  • male
  • morbidity
  • mortality
  • multicenter study
  • placebo
  • priority journal
  • radioimmunoassay
  • randomized controlled trial
  • statistical significance
  • treatment outcome
  • valsartan

Get free article suggestions today

Mendeley saves you time finding and organizing research

Sign up here
Already have an account ?Sign in

Find this document


  • Cohn J.N.

  • Anand I.S.

  • Latini R.

  • Masson S.

  • Chiang Y.-T.

  • Glazer R.

Cite this document

Choose a citation style from the tabs below

Save time finding and organizing research with Mendeley

Sign up for free